Material and Methods. This was an observational multicenter study. Pregnant women who gave birth while infected by SARS CoV2 during the Omicron waves were included. Patients were divided into 2 groups: the "booster vaccination" group included pregnant women who had completed vaccination and had received an additional dose of vaccine during pregnancy; the "non-booster vaccination" group included pregnant women who had completed primary vaccination without booster shots. Data about obstetrical and neonatal outcomes in both groups were compared.Results. In total, 59 patients were included: 41 received booster shots during the current pregnancy, and 18 did not. Asymptomatic forms were seen in 58.5% of the "booster vaccination" group versus 16.6% of the "non-boosted vaccination" group with p = 0.003. The need for cesarean delivery was reduced from 72.2% to 41.4% with p = 0.028. The length of hospitalization was reduced from 4.67 ± 4 days in the "non-boosted vaccination" group to 1.98 ± 0.93 days in the booster vaccination group with p = 0.001. The booster vaccination allowed reduced rates of prematurity with p = 0.011 and neonatal intensive care admissions with p = 0.007. Conclusions.The COVID-19 booster vaccination seems to be beneficial during the Omicron waves. It improved obstetrical and neonatal outcomes. So, pregnant women could be advised to get a booster dose of the COVID-19 vaccine when they get pregnant.

Objective. The aim of our study was to investigate the impact of antenatal diagnosis of PA on blood loss, blood transfusions, and maternal and neonatal morbidity and mortality. Materials and Methods. This is a monocenter retrospective study including all patients who had failed manual removal of the placenta or evidence of placental invasion at the surgery. The patients included were divided into 2 groups:-Group 1: patients with an antenatal diagnosis according to the ultrasounds or magnetic resonance imaging data.-Group 2: patients with unexpected placenta accreta.Then, we compared blood loss estimated by Gross formula, transfusions, and maternal and neonatal morbidity in both groups.Results. In our series, 57 cases of PA were included: 35 patients with antenatal diagnosis (group 1) and 22 with unexpected PA (group 2). The bleeding estimation was 1610 ± 908 ml in group 1 versus 2480 ± 1317 ml in group 2, with p = 0.007. The need for transfusion was reduced from 95.4 % to 17 % when PA was diagnosed antenatally with p = 0.001. Unexpected PA was correlated with an increased risk of severe bleeding with OR 2.35; 95%CI 1.08-5.62 and transfusion requirements with OR 1.85; 95%CI: 1.18-6.1. However, expected PA was correlated with a higher risk of prematurity with OR 2.04, 95%CI 1.05-4.8. Conclusions.The antenatal diagnosis of placenta accreta allowed better maternal outcomes by reducing the blood loss and transfusions requirements. However, it increased the incidence of planned preterm birth.